
|Videos|April 16, 2022
WATCH: A paradigm shift in the management of TED
Author(s)Andrew G. Lee, MD
Andrew Lee, MD, and Elizabeth Fortin, MD, discuss a paradigm shift in the treatment of thyroid eye disease with the new FDA approved medicine for managing TED.
Advertisement
In this week's discussion, Andrew Lee, MD, and Elizabeth Fortin, MD, disucss Teprotumumab, the first and only FDA approved medicine to treat thyroid eye disease (TED). They talk about the impact the drug can have on patients, cost considerations and how to use the treatment in the clinic.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved by FDA
2
REGENXBIO completes enrollment in ATMOSPHERE and ASCENT trials of sura-vec in wet AMD
3
Q&A: Inder Paul Singh, MD, explores technician empowerment via the Academy Technician Training Platform
4
Increasing the knowledge base of GA is key to individualizing patient therapy
5